Screening for latent tuberculosis infection in patients who are candidate for biological therapies in Spain? A multidisciplinary survey-Reference-Cited by-同舟云学术

Screening for latent tuberculosis infection in patients who are candidate for biological therapies in Spain? A multidisciplinary survey

Published:2018-10 Issue:10 Volume:54 Page:510-517
ISSN:1579-2129
Container-title:Archivos de Bronconeumología (English Edition)
language:en
Short-container-title:Archivos de Bronconeumología (English Edition)

Author:

Quirós Sarai,de la Rosa David,Uranga Ane,Madero Rosario,Amaro Rosanel,Bruguera Nuria,García Julia A.,Gómez C.,Iturbe David,Lera Rubén,Luque Lydia,Martínez Abel J.,Mínguez Patricia,Navarro Annie,Sánchez Gema,Suárez-Cuartín Guillermo

Publisher

Elsevier BV

Reference28 articles.

1. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent;Keane;N Engl J Med,2001

2. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor;Mohan;Clin Infect Dis,2004

3. New challenges for the pulmonologist in the diagnosis of latent tuberculosis infection: biological treatment and pulmonary tuberculosis;Hernández González;Arch Bronconeumol,2011

4. Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era;Nacci;Best Pract Res Clin Rheumatol,2011

5. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Timeline and Infectious Disease Evaluation of Candidates to New Therapies;Infectious Complications in Biologic and Targeted Therapies;2022

2. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies;Gastroenterología y Hepatología (English Edition);2021-10

3. Riesgo de infección asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biológicas en enfermedad inflamatoria intestinal y artritis reumatoide. Estrategias de prevención;Gastroenterología y Hepatología;2021-10